Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Add To Watchlist

Recent & Breaking News (NDAQ:RDHL)

Bioassociate Reiterated PT on RedHill Biopharma Following Q2 Report

PR Newswire August 20, 2013

RedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results With RHB-104 and Plans for a Phase IIa Study

Globe Newswire July 30, 2013

RedHill Biopharma Reports Results for the Second Quarter of 2013

Globe Newswire July 22, 2013

RedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program

Globe Newswire July 11, 2013

RedHill Biopharma to Present at the JMP Securities Annual Healthcare Conference in New York

Globe Newswire July 3, 2013

IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product

Globe Newswire June 18, 2013

RedHill Biopharma Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014

Globe Newswire June 18, 2013

RedHill Biopharma Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis

Globe Newswire June 5, 2013

RedHill Biopharma Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension

Globe Newswire May 29, 2013

RedHill Biopharma to Present at the Jefferies 2013 Global Healthcare Conference in New York

Globe Newswire May 28, 2013

RedHill Biopharma Reports Financial Results for the First Quarter of 2013

Globe Newswire May 2, 2013

Bioassociate Announces Valuation Report on RedHill Biopharma, Ltd.

PR Newswire April 3, 2013

IntelGenx Submits New Drug Application for Anti-Migraine VersaFilm(TM)

Globe Newswire March 27, 2013

RedHill Biopharma Submits New Drug Application to U.S. FDA for RHB-103 Anti-Migraine Oral Thin Film

Globe Newswire March 27, 2013

RedHill Biopharma Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan

Troy Schwensen March 19, 2013

RedHill Biopharma to Present at the 25th Annual ROTH Conference

Troy Schwensen March 6, 2013

RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Oncology Support Anti-Emetic)

Troy Schwensen February 25, 2013

RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results

Troy Schwensen February 19, 2013

RedHill Biopharma Announces Notice of Allowance From the United States Patent and Trademark Office for Its Cardio Drug RHB-101

Troy Schwensen February 19, 2013

RedHill Biopharma Announces Date of 2012 Financial Results and Corporate Update Conference Call

Troy Schwensen February 14, 2013